All In Biotech

Drug Trial Radar · NCT05438043

A Study of Daratumumab

A Phase 3b, Multicenter, Open-label, Daratumumab Long-term Extension Study

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

214

Actual

Start

Dec 15, 2022

Primary completion

Jan 31, 2029

Study completion Jan 31, 2029

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jun 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R\&D) studies that use daratumumab as part of the study treatment regimen: access for all participants regardless of treatment group in daratumumab studies and access to participants in daratumumab-containing arms in the non-daratumumab studies will be allowed from studies which have reached clinical cutoff for final analysis. Certain long-term safety data will continue to be collected from study participants.

Conditions

  • Multiple Myeloma

Interventions

  • DaratumumabDrug

    Daratumumab will be administered either intravenously or subcutaneously.

  • CarfilzomibDrug

    Carfilzomib will be administered intravenously.

  • DexamethasoneDrug

    Dexamethasone will be administered either orally or intravenously.

  • LenalidomideDrug

    Lenalidomide will be administered orally.

  • PomalidomideDrug

    Pomalidomide will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Serious Adverse Events (SAEs)Time frame: 3 years 7 months
  2. Number of Participants with AEs of Special Interest (AESI)Time frame: 3 years 7 months
  3. Number of Participants with Pregnancies or Partner PregnanciesTime frame: 3 years 7 months
  4. Number of Participants with Abnormal Pregnancies as SAETime frame: 3 years 7 months

Locations

92 sites in 17 countries. Site status is shown where the registry gives one.

  • University of Miami Sylvester Cancer Center

    Miami, Florida

  • Emory University

    Atlanta, Georgia

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan

  • Barnes-jewish Hospital

    St Louis, Missouri

  • Icahn School of Medicine at Mount Sinai - The Derald H. Ruttenberg

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Baylor University Medical Center

    Dallas, Texas

  • ZAS Cadix

    Antwerp, Belgium

  • Hospital das Clinicas da Universidade Estadual de Campinas UNICAMP

    Campinas, Brazil

  • Liga Norte Riograndense Contra O Cancer

    Natal, Brazil

  • Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS

    Porto Alegre, Brazil

  • Ministerio da Saude Instituto Nacional do Cancer

    Rio de Janeiro, Brazil

  • Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)

    Rio de Janeiro, Brazil

  • Real e Benemerita Associacao Portuguesa de Beneficencia

    São Paulo, Brazil

  • Clinica Medica Sao Germano LTDA

    São Paulo, Brazil

  • Peking Union Medical College Hospital

    Beijing, China

  • Beijing Chaoyang Hospital

    Beijing, China

  • Peking University First Hospital

    Beijing, China

  • Peking University People's Hospital

    Beijing, China

  • The First Bethune Hospital of Jilin University

    Changchun, China

  • West China Hospital Si Chuan University

    Chengdu, China

  • Fujian Medical University

    Fuzhou, China

  • Guangdong General Hospital

    Guangzhou, China

  • Nanfang Hospital

    Guangzhou, China

  • First Affiliated Hospital Medical School of Zhejiang University

    Hangzhou, China

  • First affiliated Hospital of Zhejiang University

    Hangzhou, China

  • Shanghai Changzheng Hospital

    Shanghai, China

  • Ruijin Hospital Shanghai Jiao Tong University

    Shanghai, China

  • Renji Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, China

  • Tianjin cancer hospital

    Tianjin, China

  • Institute of Hematology and Blood Diseases Hospital

    Tianjin, China

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, China

  • Henan Cancer Hospital

    Zhengzhou, China

  • Fakultni nemocnice Brno

    Brno, Czechia

  • Fakultni nemocnice Plzen, Hemato-onkologicke oddeleni (Main)

    Pilsen, Czechia

  • Všeobecná fakultní nemocnice v

    Prague, Czechia

  • Aarhus University Hospital

    Aarhus N, Denmark

  • Centre Hospitalier Universitaire (CHU) de Caen

    Caen, France

  • CHU Nantes

    Nantes, France

Showing 40 of 92 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.